

| INFORMATION DISCLOSURE CITATION IN AN APPLICATION Mailed on: August 4, 2004 | | Application No. 10/647,544 | | Inventor Alexandros Makriyannis et al | |
|--|--------------|---|--|--|-------|
| | | Title Keto Cannabinoids With Therapeutic Indications | | | |
| | | Filing Date 08/25/2003 | Group Art Unit 1625 | Docket No. UCONAP/207/US | |
| UNITED STATES PATENT DOCUMENTS | | | | | |
| Examiner Initial | Document No. | Date | Name | | Class |
| CA | 09/600786 | 11/24/99 | Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 00/32200 enclosed herewith) | | |
| CA | 09/701989 | 6/9/99 | Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 99/64389 enclosed herewith) | | |
| CA | 10/110865 | 10/18/00 | Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28497 enclosed herewith) | | |
| CA | 10/110830 | 10/18/00 | *1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28329 enclosed herewith) | | |
| CA | 10/110812 | 10/18/00 | Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28498 enclosed herewith) | | |
| CA | 10/110862 | 10/18/00 | Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/29007 enclosed herewith) | | |
| CA | 10/111059 | 10/18/00 | Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28557 enclosed herewith) | | |
| CA | 10/483482 | 7/11/02 | *1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 03/005960 enclosed herewith) | | |

| | | | | |
|---|--------------|---|--|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | | Title Keto Cannabinoids With Therapeutic Indications | | |
| | | Filing Date 08/25/2003 | Group Art Unit 1625 Docket No. UCONAP/207/US | |
| Mailed on: August 4, 2004 | | | | |
| CA | 10/493093 | 10/28/02 | Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 03/35005 enclosed herewith) | |
| CA | 10/790498 | 3/1/04 | Makriyannis et al | |
| CA | 2002/0119972 | 8/29/02 | Leftheris et al | |
| CA | 2003/0120094 | 6/26/03 | *1* Makriyannis et al | |
| CA | 2003/0149082 | 8/7/03 | Makriyannis et al | |
| CA | 2004/0077649 | 4/22/04 | Makriyannis et al | |
| CA | 2004/0077851 | 4/22/04 | Makriyannis et al | |
| CA | 2004/0087590 | 5/6/04 | Makriyannis et al | |
| CA | 3041343 | 6/26/62 | Jucker et al | |
| CA | 3465024 | 9/2/69 | Brownstein et al | |
| CA | 3573327 | 3/30/71 | *1* Miyano | |
| CA | 3577458 | 5/4/71 | Brownstein et al | |
| CA | 3886184 | 5/27/75 | *1* Matsumoto et al | |
| CA | 3897306 | 7/29/75 | *1* Vidic | |
| CA | 3915996 | 10/28/75 | *1* Wright | |
| CA | 3928598 | 12/23/75 | Archer | |
| CA | 3944673 | 3/16/76 | Archer | |
| CA | 3953603 | 4/27/76 | Archer | |
| CA | 4036857 | 7/19/77 | *1* Razdan et al | |
| CA | 4054582 | 10/18/77 | Blanchard et al | |
| CA | 4087545 | 5/2/78 | Archer et al | |
| CA | 4087546 | 5/2/78 | Archer et al | |
| CA | 4087547 | 5/2/78 | Archer et al | |
| CA | 4088777 | 5/9/78 | Archer et al | |
| CA | 4102902 | 7/25/78 | Archer et al | |
| CA | 4152450 | 5/1/79 | Day et al | |
| CA | 4171315 | 10/16/79 | Ryan et al | |
| CA | 4176233 | 11/27/79 | *1* Archer et al | |
| CA | 4179517 | 12/18/79 | *1* Mechoulam | |
| CA | 4188495 | 2/12/80 | Althuis et al | |
| CA | 4208351 | 6/17/80 | Archer et al | |
| CA | 4278603 | 7/14/81 | Thakkar et al | |
| CA | 4282248 | 8/4/81 | Mechoulam et al | |
| CA | 4395560 | 7/26/83 | Ryan | |

| | | | | |
|--|----------------|--|---|------------------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | | Title Keto Cannabinoids With Therapeutic Indications | | |
| | | Filing Date 08/25/2003 | Group Art Unit 1625 | Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | | | |
| CA | 4497827 | 2/5/85 | Nelson | |
| CA | 4550214 | 10/29/85 | Mehta | |
| CA | 4758597 | 7/19/88 | Martin et al | |
| CA | 4812457 | 3/14/89 | Narumiya | |
| CA | 4876276 | 10/24/89 | *1* Mechoulam | |
| CA | 4885295 | 12/5/89 | Bell et al | |
| CA | 5053548 | 10/1/91 | Tanaka et al | |
| CA | 5068234 | 11/26/91 | D'Ambra et al | |
| CA | 5147876 | 9/15/92 | Mizuchi et al | |
| CA | 5223510 | 6/29/93 | Gubin et al | |
| CA | 5284867 | 2/8/94 | *1* Kloog | |
| CA | 5324737 | 6/28/94 | D'Ambra et al | |
| CA | 5434295 | 7/18/95 | Mechoulam et al | |
| CA | 5440052 | 8/8/95 | *1* Makriyannis et al | |
| CA | 5462960 | 10/31/95 | Barth et al | |
| CA | 5489580 | 2/6/96 | Makriyannis et al | |
| CA | 5521215 | 5/28/96 | Mechoulam | |
| CA | 5532237 | 7/2/96 | Gallant et al | |
| CA | 5538993 | 7/23/96 | *1* Mechoulam | |
| CA | 5605906 | 2/25/97 | Lau | |
| CA | 5607933 | 3/4/97 | D'Ambra et al | |
| CA | 5618955 | 4/8/97 | Mechoulam et al | |
| CA | 5624941 | 4/29/97 | *1* Barth et al | |
| CA | 5635530 | 6/3/97 | Mechoulam | |
| CA | 5688825 | 11/18/97 | Makriyannis et al | |
| CA | 5747524 | 5/5/98 | Cullinan et al | |
| CA | 5744459 | | Makriyannis et al | |
| CA | 5804601 | 9/8/98 | Kato et al (appears equivalent to EP0737671) | |
| CA | 5817651 | 10/6/98 | D'Ambra et al | |
| CA | 5872148 | 2/16/99 | *1* Makriyannis et al | |
| CA | 5874459 | 2/23/99 | Makriyannis et al | |
| CA | 5925628 | 7/20/99 | Lee et al | |
| CA | 5925768 | 7/20/99 | Barth et al | |
| CA | 5932610 | 8/3/99 | *1* Shohami et al | |
| CA | 5948777 | 9/7/99 | Bender et al | |

| | | | | |
|--|---------|---|---|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | | Title Keto Cannabinoids With Therapeutic Indications | | |
| | | Filing Date 08/25/2003 | Group Art Unit 1625 Docket No. UCONAP/207/US | |
| Mailed on: August 4, 2004 | | | | |
| CA | 6013648 | 1/11/00 | *1* Rinaldi et al (appears equivalent to FR2735774) | |
| CA | 6028084 | 2/22/00 | Barth et al | |
| CA | 6096740 | 9/1/00 | Mechoulam | |
| CA | 6127399 | 10/3/00 | Yuan | |
| CA | 6166066 | 12/26/00 | *1* Makriyannis et al | |
| CA | 6284788 | 10/4/01 | Mittendorf et al (appears equivalent to EP860168) | |
| CA | 6391909 | 5/21/02 | Makriyannis et al | |
| CA | 6579900 | 6/17/03 | Makriyannis et al | |
| CA | 6610737 | 8/26/03 | Garzon et al | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | Document No. | Date | Country | Name | Translation |
|------------------|--------------|----------|---------|--|-------------|
| | EP0276732 | 8/3/88 | EP | *1* Hoffman La Roche | |
| CA | EP0471609 | 6/29/93 | EP | Gubin et al, in French, front page only (English bibliography and abstract, appears equivalent to US5223510) | |
| CA | EP0737671 | 10/16/96 | EP | Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601) | |
| CA | EP0860168 | 9/4/01 | EP | Mittendorf et al, in German, front page only (including English bibliography, appears equivalent to US6284788) | |
| CA | FR2240003 | 5/27/75 | FR | *1* Matsumoto et al, in French (including English bibliography and abstract, appears equivalent to US3886184) | |

| | | | | | |
|--|--------------|---|----|---|-----------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | Application No. 10/647,544 | | Inventor Alexandros Makriyannis et al | |
| | | Title Keto Cannabinoids With Therapeutic Indications | | | |
| | | Filing Date 08/25/2003 | | Group Art Unit 1625 | Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | | | | |
| CA | FR2735774 | 1/11/00 | FR | *1* Barth et al, in French (including English bibliography and abstract, appears equivalent to US6013648) | |
| CA | GB2027021A | 2/13/80 | GB | Mechoulam et al, in English (appears equivalent to US4282248) | |
| CA | JP57098228 | 6/18/82 | JP | Noda et al, in Japanese (including English bibliography and abstract) | |
| CA | WO 00/32200 | 6/8/00 | | Makriyannis et al, in English | |
| CA | WO 01/28329 | 4/26/01 | | *1* Makriyannis et al, in English | |
| CA | WO 01/28497 | 4/26/01 | | Makriyannis et al, in English | |
| CA | WO 01/28498 | 4/26/01 | | Makriyannis et al, in English | |
| CA | WO 01/28557 | 4/26/01 | | Makriyannis et al, in English | |
| CA | WO 01/29007 | 4/26/01 | | Makriyannis et al, in English | |
| CA | WO 01/32169 | 5/10/01 | | Fride et al, in English | |
| CA | WO 01/58869 | 8/16/01 | | Pandit et al, in English, first page only (including bibliography and abstract, appears equivalent to US2002/0119972) | |
| CA | WO 03/005960 | 1/23/03 | | *1* Makriyannis et al, in English | |
| CA | WO 03/020217 | 3/13/03 | | Makriyannis et al , in English | |
| CA | WO 03/035005 | 5/1/03 | | Makriyannis et al, in English | |
| CA | WO 03/063758 | 8/7/03 | | Garzon et al, in English | |
| CA | WO 03/064359 | 8/7/03 | | Garzon et al, in English | |
| CA | WO 97/00860 | 1/9/97 | | Rinaldi et al, in French (including English bibliography and abstract, appears equivalent to US6013648) | |
| CA | WO 99/57107 | 11/11/99 | | *1* Makriyannis et al, in English | |
| CA | WO 99/64389 | 12/16/99 | | Makriyannis et al, in English | |

| | | | | |
|---|--|---|--|-----------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | | Title Keto Cannabinoids With Therapeutic Indications | | |
| | | Filing Date 08/25/2003 | Group Art Unit 1625 | Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | |
| Examiner Initial | | | | |
| <i>CA</i> | Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A.; "(R)-Methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability"; J. Med. Chem.; 37(12); 1889-1893; 1994; CODEN: JMCMAR; ISSN: 0022-2623; XP002040932 | | | |
| <i>CA</i> | *1* Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenerated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768 | | | |
| <i>CA</i> | *** Archer et al; "cannabinoids, synthesis approaches to 9-ketocannabinoids."; J. Org. Chem.; vol. 42; no. 13; 2277-2284; (1977) | | | |
| <i>CA</i> | *1* Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106. (abstract only) | | | |
| <i>CA</i> | *1* Barnett-Norris et al; "Exploration of biologically relevant conformations of anandamide, . . ."; J. Med. Chem.; vol. 41; 4861-4872; 1998 | | | |
| <i>CA</i> | *1* Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36 | | | |
| <i>CA</i> | *1* Belgaonkar et al; "synthesius of isocoumarins"; Indian J. Chem; vol. 13; no. 4; 336-338; 1975 (abstract only) | | | |
| <i>CA</i> | Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; "Functional Role Of High-Affinity Anandamide Transport, as Revealed By Selective Inhibition"; Science; vol. 277; 1094-1097; 1997 | | | |
| <i>CA</i> | Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; "Identification and Functional Role of High Affinity Anandamide Transport"; The Neurosciences Institute (1 page) | | | |
| <i>CA</i> | Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000 Nov; 108(1-2):169-90 | | | |

| | | |
|--|---|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | |
| CA | Berglund et al; "Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors . . ."; Prostaglandins, leukotrienes ands essential fatty acids; 59(2); 111-118; (1998). (abstract only) | |
| CA | Bodnar, V.N., Lozinskii, M.O., Pel'kis, P.S.; "Synthesis fo 2,5-disubstituted 1,3,4-oxadiazoles and 1,4-dihydro-1,2,4,5-tetrazines"; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 48(12); 1308-1311; 1982 (abstract only) | |
| CA | Bracey, M et al, Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002; 298(5599): 1793-1796 | |
| CA | *1* Brenneisen R, Pgli A, Elsohly MA, Henn V, Spiess Y: The effect of orally and rectally administered - 9 - tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. (abstract only) | |
| CA | *1* *** Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876. | |
| CA | *1* Brown et al; "Synthesis and hydroboration of (-)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl analogues for the chiral hydroboration of representative alkenes"; J. Org. Chem.; 55(4); 1217-1223; (1990) | |
| CA | *1* Buckley NE, McCoy KI, Mpzey E et al, "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor"; Eur. J Pharmacol (2000) 396:141-149. | |
| CA | *1* Burstein et al; "detection of cannabinoid receptors . . ."; Biochem. Biophys. Res. Commun.; vol. 176(1); 492-497; 1991 (abstract only) | |
| CA | Busch-Peterson et al; "Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs"; J. Med. Chem.; 39; 3790-3796; (1996) | |
| CA | *1* Calignano A, La Rana G, Diuffrida A, Piomelli D; "Control of pain initiation by endogenous cannabinoids"; Nature (1998) 394:277-291. (abstract only) | |
| CA | Calignano A., La Rana G., Beltramo, M., Makriyannis A., Piomelli D; "Potentiation of Anandamide Hypotension by the Transport Zinhibitor, AM404"; Eur. J. Pharmacol.; 1997; 337 R1-R2 | |

| | | | | |
|--|---|---|--|-----------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | | Title Keto Cannabinoids With Therapeutic Indications | | |
| | | Filing Date 08/25/2003 | Group Art Unit 1625 | Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | | | |
| CA | Calignano A., La Rana G., Makriyannis A., Lin. S., Beltramo M., Piomelli D; "Inhibition of Intestinal Motility by Anandamide, an Endogenous Cannabinoid"; Eur. J. Pharmacol.; 1997; 340 R7-R8 | | | |
| CA | Campbell FA et al; "Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review"; BMJ. 2001 Jul 7;323(7303):13-6 | | | |
| CA | *1* Charalambous A. et al; "5'-azido 8-THC: A Novel Photoaffinity Label for the Cannabinoid Receptor"; J. Med. Chem., 35, 3076 - 3079 (1992) | | | |
| CA | *1* Charalambous A. et al; "Pharmacological evaluation of halogenated . . ."; Pharmacol. Biochem. Behav.; vol. 40; no. 3; 509-512; 1991 | | | |
| CA | *1* Cheng et al; "Relationship Between the Inhibition Constant (Ki) and the concentration of Inhibitor which causes 50% Inhibition (IC50) of an Enzymatic Reaction"; Biochem. Pharmacol., 22, 3099-3102, (1973) (abstract only) | | | |
| CA | Cherest M., Luscindi X.; "The action of acetyl chloride and of acetic anhydride on the lithium nitronate salt of 2-phenylnitroethane . . ."; Tetrahedron; 42(14); 3825-3840; 1986; in French with English abstract | | | |
| CA | Cherest M., Lusinchi X.; "A novel electrophilic N-amidation via electron deficient complexes: action of ferric chloride on N-acetyloxyamides"; Tetrahedron Letters; 30(6); 715-718; 1989 | | | |
| CA | *1* Colombo G, Agabio R, Diaz G. et al; "Appetite suppression and weight loss after the cannabinoid antagonist SR141716"; Life Sci. (1998) 63-PL13-PL117. (abstract only) | | | |
| CA | *** Compton D.R. et al; J. Pharmacol. Exp. Ther.; 260; 201-209; 1992 | | | |
| CA | *1* Compton et al; "Synthesis and pharmacological evaluation of ether and related analogues of delta8-. delta9- and delta9,11-tetrahydrocannabinol"; J. Med. Chem; vol. 34; no. 11; 3310-3316; 1991 | | | |
| CA | *1* Consroe P, Musty R, Rein J, Tillery W, Pertwee R; "The perceived effects of smoked cannabis on patients with multiple sclerosis"; Eur. Neurol. (1997) 38-44-48. (abstract only) | | | |
| CA | Coxon et al; "Derivatives of nolinone"; Aust. J. Chem.; 23; 1069-1071; (1970) (abstract only) | | | |
| CA | *1* Crawley et al; "Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents"; Pharmacology Biochemistry and Behavior; vol. 46; 967-972; 1993 | | | |

| | | |
|--|--|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | |
| CA | D'Ambra et al; "C-attached aminoalkylindoles: potent cannabinoid mimetics"; Bioorg. & Med. Chem. Lett., 1996, 6(1), 17-22 | |
| CA | *** D'Amour F.E., Smith D.L.; J. Pharmacol. Exp. Ther.; 72; 74-79; 1941 | |
| CA | Demuynck L. et al; "Rearrangement of Indolo[2,3-a]quinolizidines to derivatives with E-azaaspidospermane skeleton"; Tetrahedron Letters; 30(6) 710-722; 1989; in French with English abstract | |
| CA | *1* DePetrocellis L, Melck D, Palmisano A. et al; "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation"; Proc. Natl. Acad. Sci. USA (July 1998) 95:8375-8380. | |
| CA | Desarnaud F., Cadas H., Piomelli D.; "Anandamide amidohydrolase activity in rat brain microsomes"; J. Biol. Chem.; 270; 6030-6035; (1995) | |
| CA | Deutsch D.G. et al; "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to cannabinoid receptor"; Biochem. Biophys. Res. Commun. 231(1); 217-221; 1997; CODEN: BBRCA9; ISSN:0006-291X; XP002040933 | |
| CA | Deutsch D.G., Chin S.A.; "Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist"; Biochemical Pharmacology; 46(5); 791-796; 1993 | |
| CA | *1* Devane, W.A. et al; "Determination and Characterization of a Cannabinoid Receptor in a Rat Brain"; Mol. Pharmacol., 34, 605 - 613 (1988). (abstract only) | |
| CA | *1* Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L.; "Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action"; Trends Neurosci. (1998) 21:521 - 528. | |
| CA | *** Dodd, P.R. et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981). | |
| CA | *1* Dominiami et al; "Synthesis of 5-(tert-Alkyl)resorcinols"; J. Org. Chem. 42(2); 344-346; (1977) | |
| CA | Drake et al, "classical/nonclassical hybrid cannabinoids"; J. Med. Chem.; vol. 41(19); 3596-3608 (1998) | |
| CA | Edery et al; "Activity of novel aminocannabinoids in baboons"; J. Med. Chem.; 27; 1370-1373 (1984) | |
| CA | Eissenstat et al; "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics"; J. Med. Chem. 1995, Vol. 38, No. 16, pp. 3094-3105; XP 000651090 | |
| CA | Fahrelnoltz, K. E., Lurie, M. and Kierstead, AR. W.; "The Total Synthesis of dl- Δ 9-Tetrahydrocannabinol and Four of Its Isomers"; J. Amer. Chem. Soc. 1967, 89(23), 5934-5941 | |

| | | |
|--|--|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group/Art Unit 1625 Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | |
| CA | *1* Fahrenholz; "The synthesis of 2 metabolites of (-)-delta eight-tetrahydrocannabinol"; J. Org. Chem.; vol. 37(13); 1972; XP002111824 | |
| CA | Fisera, L., Kovac, J., Lesco, J., Smahovsky, V.; "Furan derivatives. Part CLVI. 1,3-dipolar cycloadditions of heterocycles. V. Reaction of C-acetyl-N-phenylnitrilimine with furan derivatives"; Chemicke Zvesti; 35(1); 93-104 1981 (abstract only) | |
| CA | *1* Fride, E. & Mechoulam, R.; "Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent"; European Journal of Pharmacology, vol. 231; 313-314; 1993. | |
| CA | Galiegue S et al. ; "Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations"; Eur J Biochem.; 1995 Aug 15;232(1):54-61. (abstract only) | |
| CA | *1* Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M.; "Structure activity relationships of tetrahydrocanabinol analogs on human cannabinoid receptors"; Bioorg. Med. Chem. Lett. 1996, 6(2), 189-194 | |
| CA | *1* Gold et al; "A comparison of the discriminative stimulus properties of delta9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys"; J. Pharmacol. Exp. Ther.; vol. 262(2); 479-486; 1992 | |
| CA | *1* *** Green K. Marijuana smoking vs. cannabinoids for glaucoma therapy. Arch. Ophibalmol. (1998) feb 433-1437. | |
| CA | *1* Hampson, A.J., Grimaldi M. Axirod J. Wink D; "Cannabidiol and (-) 9 tetrahydrocannabinol are neuroprotective antioxidants"; Proc. Natl Acad Sci. USA (July 1998) 95; 8268-8273. | |
| CA | *1* Hargreaves, K. et al; "A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia"; Pain; 32; 77-88; (1988) (abstract only) | |
| CA | *1* *** Hemming M, Yellowlees PM; "Effective treatment of Tourette's syndrome with marijuana"; J. Psychopharmacol, (1993) 7:389-391. | |
| CA | *1* Herzberg U, Eliav E, Bennett GJ, Kopin IJ; "The analgesic effects of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain"; Neurosci. Letts. (1997) 221; 157-160. | |
| CA | Hillard C. J., Edgemon, W. S., Jarrahian W., Campbell, W. B; "Accumulation of N-Arachidonoylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion"; Journal of Neurochemistry; 69; 631-638 (1997) | |

| | | |
|--|---|---|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | |
| CA | Horrevoets A.J.G et al; "Inactivation of escherichia coli outer membrane phospholipase A by the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 247-253; 1991 | |
| CA | Horrevoets A.J.G et al; "Inactivation of reconstituted escherichia coli outer membrane phospholipase A by membrane-perturbing peptides results in an increased reactivity towards the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 255-261; 1991 | |
| CA | Howlett et al; "Azido and isothicyanato substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction"; Journal of Neurochemistry; vol. 74(5) (2000) 2174-2181; XP001097394 | |
| CA | *1* Howlett et al; "Stereochemical effects of 11-OH-delta 8 tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor"; Neuropharmacology; vol. 29(2); 161-165; 1990 | |
| CA | Huffman et al; "3-(1',1'-dimethylbutyl)--deoxy-delta 8THC and related compounds: synthesis of selective ligands for the CB2 receptor"; Bioorganic and Medicinal Chemistry; vol. 7; 2905-2914; (1999) | |
| CA | Huffman et al; "Stereoselective synthesis of the epimeric delta 7-tetrahydocannabinols"; tetrahedron; vol. 51(4); 1017-1032; (1995) | |
| CA | *1* Huffman et al; "Synthesis of 5',11 dihydroxy delta 8 tetrahydrocannabinol"; Tetrahedron, vol. 53(39), pp 13295-13306 (1997) | |
| CA | *1* Huffman et al; "Synthesis of a tetracyclic, conformationally constrained analogue of delta8-THC"; Bioorganic & Medicinal Chemistry; vol. 6(12); 2281-2288; 1998; XP002123230 | |
| CA | *1* Huffman et al; "Synthesis of both enantiomers of Nabilone from a common intermediate. Enantiodivergent synthesis of cannabinoids"; J. Org. Chem.; 1991, 56, 2081-2086 | |
| CA | *1* *** Joy JE, Wagtson SJ, Benson JA; "Marijuana and Medicine Assessing the Science Base"; National Academy Press, Washington, DC, USA (1999). | |
| CA | Kaminski NE; "Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors"; J Neuroimmunol. 1998 Mar 15;83(1-2):124-32 | |
| CA | Kawase M. et al; "Electrophilic aromatic substitution with N-methoxy-N-acylnitrenium ions generated from N-chloro-N-methoxyamides: synthesis of nitrogen heterocyclic compounds bearing a N-methoxyamide group"; J. Org. Chem.; 54; 3394-3403; 1989 | |

| | | |
|--|--|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 |
| Mailed on: August 4, 2004 | | |
| <i>CA</i> | Khanolkar A., Abadji V., Lin S., Hill W., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A.; "Head group analogues of arachidonylethanolamide, the endogenous cannabinoid ligand"; <i>J. Med. Chem.</i> ; vol. 39(22); 4515-4519; (1996) | |
| <i>CA</i> | Khanolkar et al; "Molecular probes for the cannabinoid receptors"; <i>Chemistry and Physics of Lipids</i> ; 108; 37-52; (2000) | |
| <i>CA</i> | Klein T.W. et al, "The cannabinoid system and cytokine network"; <i>Proc Soc Exp Biol Med</i> . 2000 Oct; 225(1):1-8; (abstract only) | |
| <i>CA</i> | Klein TW et al, "Cannabinoid receptors and immunity"; <i>Immunol Today</i> ; 1998 Aug; 19(8):373-81 | |
| <i>CA</i> | Koutek B. et al; "Inhibitors of arachidonyl ethanolamide hydrolysis"; <i>J. Biol. Chem.</i> ; 269(37); 22937-40; 1994; CODEN: JBCHA3; ISSN: 0021-9258; XP002040931 | |
| <i>CA</i> | Kumar RN, et al; "Pharmacological actions and therapeutic uses of cannabis and cannabinoids"; <i>Anesthesia</i> , 2001, 56: 1059-1068 (abstract only) | |
| <i>CA</i> | Lan, R et al; "Structure activity relationships of pyrazole derivatives as cannabinoid receptor antagonists"; <i>J. Med. Chem.</i> ; vol. 42(4); 769-776; (1999) | |
| <i>CA</i> | *1* Lavalle et al; "Efficient conversion of (1R, 5R)-(+)-alpha-pinene to (1S, 5R)-(-)-nopinene"; <i>J. Org. Chem.</i>; vol. 51(8); 1362-1365; (1986) | |
| <i>CA</i> | Lin S., Khanolkar A., Fan P., Goutopolous A., Qin C., Papahadjis D., Makriyannis A.; "Novel Analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 Cannabinoid Receptors and Metabolic Stability"; <i>J. Med. Chem.</i> ; vol. 41; 5353; 1998 | |
| <i>CA</i> | *1* Loev, B., Bender, P. E., Dowalo, F., Macko, E., and Fowler, P.; "Cannabinoids. Structure-Activity Studies Related to 1,2-Dimethylheptyl Derivatives"; <i>J. Med. Chem.</i>; vol. 16(11); 1200-1206; 1973 | |
| <i>CA</i> | Lozinskii, M.O., Bodnar, V.N., Konovalikhin, S.V., D'yachenko, O.A., Atovmyan, L.O.; "Unusual transformations of arylhydrazoneyl chlorides of oxalic acid ethyl ester"; <i>Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya</i> ; 11; 2635-2637; 1990 (abstract only) | |
| <i>CA</i> | *1* Ludt, R.E. et al; "A comparison of the synthetic utility of n-butyllithium and lithium diisopropylamide in the metalations of N,N-dialkyltouamides"; <i>J. Org. Chem.</i>; 38(9); 1668-1674 (1973) | |
| <i>CA</i> | *** Maccarron M., Endocannabinoids and their actions. Vitamins and Hormones 2002;65:225-255 | |

| | | | | |
|--|---|---|--|-----------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | | Title Keto Cannabinoids With Therapeutic Indications | | |
| | | Filing Date 08/25/2003 | Group Art Unit 1625 | Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | | | |
| CA | Mackie K., Devane W.A., Hille B.; "Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells"; Mol. Pharmacol; 44; 498-0503 (1993) | | | |
| CA | *1* *** <i>Markwell et al; Anal. Biochem.</i> ; 87:206 (1978) | | | |
| CA | *1* Martin et al; "Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs"; Pharmacol. Biochem. Behav.; vol. 40(3); 471-478; 1991 | | | |
| CA | *1* Martyn CN. Illis LS, Thom J.; "Nabilone in the treatment of multiple sclerosis"; Lancet (1995) vol. 345; pp. 579. | | | |
| CA | *1* Matsumoto et al; "Cannabinoids 1,1-amino-and 1 mercapto-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyrans"; J. of Med. Chem.; vol. 20(1); 17-24; 1977; XP00211825 | | | |
| CA | *1* *** <i>Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. Psychiat. Clin. Neurosci.</i> (1990), Z40:1-4. | | | |
| CA | *1* Mavromoustakos, T. et al; "Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction"; <i>Biochimica et Biophysica Acta</i> ; vol 1281(2); 1996; XP00211823 | | | |
| CA | Mechoulam et al; "Stereochemical Requirements for cannabinoid activity"; J. Med. Chem.; 23(10); 1068-1072; (1980) | | | |
| CA | Mechoulam et al; "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative"; Tetrahedron Asymmetry; 1: 311-314; (1990) (abstract only) | | | |
| CA | *** <i>Mechoulam et al; Tetrahedron Asymmetry</i> ; 1: 315-318; (1990) | | | |
| CA | *1* *** <i>Mechoulam, "Cannabinoids as therapeutic agents"</i> ; CRC press, 1986 | | | |
| CA | *1* Meltzer et al; "An improved synthesis of cannabinol and cannabiorcol"; <i>Synthesis</i> ; 1981:985 (1981) | | | |
| CA | *** <i>Melvin et al; drug design and discovery</i> ; 13; 155-166 (1995) | | | |
| CA | Melvin et al; "Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs"; Mol. Pharmacol.; 44(5); 1008-1015 (1993) | | | |
| CA | *1* <i>Merck Index</i> ; 11th edition; "Tetrahydrcannabinols" compound no. 9142; 1989 | | | |

| | | |
|--|---|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 |
| Mailed on: August 4, 2004 | | |
| CA | *1*** Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997). | |
| CA | *1*** Morris, S.; Mechoulam, R.; and Irene, Y., Halogenation of phenols and Phenyl ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid, J. Chem. Soc., Perkin Trans. 1 1987, 1423-1427 | |
| CA | *1*** Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27. | |
| CA | *1*** Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiat. (1999) 156-195. | |
| CA | *** Nahas G, Marijuana and Medicine; 1999, Human Press Inc., Totowa, NJ | |
| CA | Neunhoeffer O., Gottschlich R.; "Acylating activity of O-acylated hydroxylamine derivatives"; Justus Liebigs Ann. Chem.; 736; 100-109; 1970; in German with English abstract | |
| CA | *1 Novak, J et al; "Cannabis, part 27, synthesis of 8-, 10- and 11-oxygenated cannabinoids; J. Chem. Soc. Perkin Trans.; 2867-2871; (1983) (abstract only) | |
| CA | *1 Nye et al; "High affinity cannabinoid binding sites in brain membranes labelled with [H]-5'-trimethylammonium delta8-tetrahydrocannabinol"; J. Pharmacol. Exp. Ther.; vol. 234(3); 784-791; 1985 | |
| CA | *** Palmer et al; current pharmaceutical design; 6; 1381-1397; (2000) | |
| CA | *1 Papahatjis et al; "A new ring-forming methodology for the synthesis of conformationally constrained bioactive molecules"; Chemistry Letters, 192; (2001) | |
| CA | *1 Papahatjis et al; "Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta8-tetrahydrocannabinols"; J. Med. Chem.; 41(7); 1195-1200; (1998) | |
| CA | Pertwee et al; "AM630, a competitive cannabinoid receptor agonist"; Life Sci. 1995, 56(23/24), 1949-1955; XP 000653566 | |
| CA | Pertwee et al; "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens"; Eur. J. Pharmacol. 1995, 284, 241-247; XP-001041044 | |
| CA | *** Pertwee et al; Br. J. Pharmacol.; 105; 980 1992 | |


| | | |
|--|---|---|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | |
| CA | *1* Pertwee; Pharmacology of cannabinoid CB1 and CB2 receptors"; <i>Pharmacol. Ther.</i> , vol. 74(2); pp129-180; (1997); XP002226467 | |
| CA | Petrov, M.L., Terent'eva, N.A., Potekhin, K.A., Struchkov, Yu. T.; .alpha.,.beta.-unsaturated thiolates and their analogs in cycloaddition reactions. XVIII. Reaction of (2-phenylethyynyl)tellurolates with C- ethoxycarbonyl-N-Phenylnitrilimine"; <i>Zhurnal Organicheskoi Khimii</i> ; 29(7); 1372-1378; (1993) (abstract only) | |
| CA | *1* *** Pinnegan-Ling D, Musty R.; Marinol and phantom limb pain: a case study. <i>Proc Inv. Cannabinoid Rea. Sec.</i> (1994):53. | |
| CA | Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xiw X-Q., Makriyannis A.; "Structural determinants for recognition and translocation by the anandamide transporter"; <i>Proc. Natl. Acad. Sci. USA</i> ; 96; 5802-5807; (1999) | |
| CA | *1* Pitt et al; "The synthesis of Deuterium, carbon-14 and carrier free tritium labelled cannabinoids"; <i>Journal of Labelled Compounds</i> ; vol. 11(4); 551-575; 1975; XP002123229 | |
| CA | *** Porreca F., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F.; "Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse"; <i>J. Pharmacol. Exp. Ther.</i> ; 230; 341-348; (1994) | |
| CA | *1* Razdan et al; "Drugs delivered from cannabinoids. 6. .Synthesis of cyclic analogues of dimethylheptylpyran"; <i>J. Med. Chem.</i> ; vol. 19(5); 719-721; 1976 (abstract only) | |
| CA | *1* Reggio et al; "Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach"; <i>J. Med. Chem. United States</i> ; vol. 36(12); 1761-1771; 1993 | |
| CA | *1* Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; and Mechoulam, R.; "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylycyclase"; <i>J. Med. Chem.</i> 1997, 40(20); 3228-3233 | |
| CA | *** Rice AS. <i>Cannabinoids and pain. Curr Opin Investig Drugs.</i> 2001 Mar;2(3):399-414 | |
| CA | *1* Richardson JD, Aanonsen I, Hargreaves KM; "Antihyperalgesic effects of a spinal cannabinoids"; <i>Eur. J. Pharmacol.</i> (1998) 346:145- 153. | |
| CA | *1* Richardson JD, Kilo S. Hargreaves KM; "Cannabinoids reduce dryperalgesia and inflammation via interaction with peripheral CB1 receptors"; <i>Pain</i> (1998) 75:111-119. | |

| | | |
|--|--|---|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al |
| | Title Keto Cannabinoids With Therapeutic Indications | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | |
| CA | Rinaldi-Carmona et al; "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"; Life Sci.; vol. 56(23/24); 1941-1947 (1995) | |
| CA | Rinaldi-Carmona et al; "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"; FEBS Lett.; 350; 240-244; (1994) | |
| CA | *1* Rompp Chemie Lexikon; Falbe and Regitz; "band 1-A-C1, 8"; Aufl, Thieme Verlag; Stuttgart, S 569-570; 1989 | |
| CA | Santus, Maria; "Studies on thioamides and their derivatives. IX. Synthesis of the derivatives of 1,2,4,5-tetrazine"; Acta Polonae Pharmaceutica; 50(2-3); 183-188; 1993 (abstract only) | |
| CA | Schatz AR et al; "Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system"; Toxicol Appl Pharmacol. 1997 Feb; 142(2):278-87 | |
| CA | *1* *** Schuel, H., Burkman, L.J., Picone, R.P., Bo, T., Makriyannis, A., <i>Cannabinoid receptors in human sperm. Mol. Biol. Cell.</i> , (1997) (8), 325a. | |
| CA | *** Serdarevich B., Caroll K.K., "Synthesis and characterization of 1- and 2-monoglycerides of anteiso fatty acids"; J. Lipid Res.; 7; 277-284; (1966) | |
| CA | Shawali, A.S., Albar, H.A.; "Kinetics and mechanism of dehydrochlorination of N-aryl-C-ethoxycarbonyl formohydrazidoyl chlorides"; Canadian Journal Of Chemistry; 64(5); 871-875; 1986 (abstract only) | |
| CA | *1* *** Shen M. Thayer SA: <i>Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol</i> (1996) 54:459-462. | |
| CA | Shim et al; "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis"; J. Med. Chem.; 1998, 41(23); 4521-4532; XP-002212407 | |
| CA | Shim et al; "Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2"; ACS Symposium series, 1999 719 (rational drug design), 165-184; XP-001095771 | |
| CA | Showalter et al; "Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands"; J. Pharmacol. Exp. Ther., 1996 278(3) 989-999; XP-001097918 | |

| | | | |
|--|---|--|-----------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | Title Keto Cannabinoids With Therapeutic Indications | | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 | Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | | |
| CA | *1* *** Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181. | | |
| CA | *1* Smith P.B. et al; "The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice"; Journal of Pharmacology and Experimental Therapeutics; vol. 270(1):219-227; 1994 | | |
| CA | *1* *** Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; Psycho-pharmacol (1996) 126:165-172. | | |
| CA | Tius et al; "Conformationally restricted hybrids of CP-55,940 and HHC: Stereoselective synthesis and activity"; Tetrahedron; 50 (9); 2671-2680; (1994) (abstract only) | | |
| CA | Twitchell, W. et al; "Cannabinoids inhibit N- and P/Q type calcium channels in cultured rat hippocampal neurons"; Journal of Neurophysiology; 78(1); 43-50; 1997 (abstract only) | | |
| CA | *** Ueda, N., Endocannabinoid hydrolases. Prostaglandins & Other Lipid Mediators 2002;68-69:521-534 | | |
| CA | *** Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R.; "Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase"; J. Neurochem.; 61(1) 352-355; (1993) | | |
| CA | *1* *** Wagner JA, Varga K, Jarai Z, Kunos G; 'Mesenteric vasodilation mediated by endothelia anandamide receptors'; Hypertension (1999) 33:429-434. | | |
| CA | *1* Watanabe, T.; Miyaura, N.; and Suzuki, A.; "Synthesis of Sterically Hindered Biaryls via the Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes"; Synlett 1992, 207-210 | | |
| CA | Wiley et al; "Structure activity relationships of indole and pyrrole derived cannabinoids"; J. Pharmacol. Exp. Ther. 1998, 285(3), 995-1004; XP-001097982 | | |
| CA | Wilson et al; "9-nor-delta8-tetrahydrocannabinol, a cannabinoid of metabolic interests"; J. Med. Chem.; 17(4); 475-476; (1974) | | |
| CA | Wilson et al; "Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs"; J. Med. Chem.; 18(7); 700-703; (1975) | | |
| CA | Wilson et al; "9-nor-9-hydrohexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols"; J. Med. Chem.; 19(9); 1165-1167; (1976) | | |

| | | | |
|---|--|---|------------------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. 10/647,544 | Inventor Alexandros Makriyannis et al | |
| | Title Keto Cannabinoids With Therapeutic Indications | | |
| | Filing Date 08/25/2003 | Group Art Unit 1625 | Docket No. UCONAP/207/US |
| Mailed on: August 4, 2004 | | | |
| <i>CA</i> | Yamada et al; "(Aminoalkyl)indole isothiocyanates as potential electrophilic affinity ligands for the brain cannabinoid receptor"; J. Med. Chem. 1996, vol. 39(10), 1967-1974 | | |
| <i>CA</i> | Yan, Guo et al; "Synthesis and pharmacological properties of 11-hydroxy-3-(1'-1'-dimethylheptyl)hexahydrocannabinol: a high affinity cannabinoid agonist"; J. Med. Chem.; vol. 37(16); 2619-2622; (1994) | | |
| <i>CA</i> | *1* Yan Guo et al; "(-)-11-hydroxy-7'-isothiocyanato-1'-1'dimethylheptyl-delta8-THC: a novel probe for the cannabinoid receptor in the brain"; J. Med. Chem.; 37(23); 3867-3870; (1994) | | |
| Examiner <i>ALIAK</i> | Date Considered | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | |

G:\AYR\saved docs\filing Docs\Uconap\uconap207us\regular\of\uconap.200.us\8-04\IDS.doc



| | | |
|---|---|------------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Application No. | Inventor |
| | 10/647,544 | Alexandros MAKRIYANNIS et al |
| | Title KETO CANNABINOIDs WITH THERAPEUTIC INDICATIONS | |
| Filing Date | Group Art Unit | Docket No. |
| Aug. 25, 2003 | 1614 | UCONAP/207/US |

UNITED STATES PATENT DOCUMENTS

| Examiner Initial | Document No. | Date | Name | Class |
|------------------|--------------|------|-----------------|-------|
| CA | 3,656,906 | | F. J. Bullock | |
| CA | 3,838,131 | | Gauthier et al. | |
| CA | 4,382,943 | | Winter et al. | |
| CA | 5,576,436 | | McCabe et al. | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | Document No. | Date | Country | Name | Translation |
|------------------|--------------|------|---------|------|-------------|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| Examiner Initial | | |
|------------------|---|--|
| CA | Database CAPLUS on STN, AN 1991: 679813, NAKAYAMA et al. "Preparation of 6H-dibenzo[b,d]pyran-6-ones and their use as aldoes reductase inhibitors", Abstract, JP 02304080 A2, 17 December 1990 (17.12.1990), see entire abstract. | |
| CA | International Search Report for International Application No. PCT/US03/26609 mailed on April 29, 2004 | |
| | | |
| | | |
| | | |

Examiner ALI ACH Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\IPATLAW51C\PATLAW51AYR saved docs\Filing Docs\Uconap\uconap207us regular of uconap.200.us\uconap207us 5-20-04